IL-33 Polyclonal Antibody, Invitrogen™

Description

• Despite its predicted molecular weight, IL-33 often migrates at a higher molecular weight in SDS-PAGE
• A suggested positive control is human lymph node tissue lysate
• PA5-20397 can be used with blocking peptide PEP-0514
• IL-33 (Interleukin-33) is a 270 amino acid, highly divergent protein belonging to the IL-1 family with an IL-1-like C-terminal domain
• IL-33 is a dual function protein that may function both as a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties
• IL-33 binds to and signals through IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6
• IL-33 activates NF-kappaB and MAP kinases, and drives production of TH2-associated cytokines from in vitro polarized TH2 cells
• In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs
• IL-33 is proteolytically converted to a mature form by CASP1 and is highly expressed in high endothelial venules found in tonsils, Peyer's patches and mesenteric lymph nodes and is almost undetectable in placenta
• Prolonged IL-33 treatment of mice led to the development of eosinophilia, splenomegaly, and severe pathological changes in mucosal organs such as lungs, esophagus and small intestine
• Recent experiments have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties
• Despite its predicted molecular weight, IL-33 will often run at higher molecular weight in SDS-PAGE
• Studies have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine, and an intracellular nuclear factor with transcriptional regulatory properties.